WASHINGTON — During recent confirmation hearings, senators from two pivotal committees closely examined the significant authority Chris Klomp currently holds and the potential implications of his role as deputy secretary of the Department of Health and Human Services (HHS) under health secretary Robert F. Kennedy Jr.
Klomp, who has been instrumental in shaping the Trump administration’s Make America Healthy Again initiative, has engaged in critical negotiations with pharmaceutical companies aimed at reducing drug prices. His responsibilities have included high-profile personnel searches and serving as a key liaison between HHS and the White House, positioning him as a central figure in health policy decision-making.
“Part of my responsibility is to enable the smooth operations of the department. I’m responsible for personnel, among other things,” Klomp stated during his testimony before the Senate Finance Committee. His confirmation could significantly affect the operational dynamics within HHS, influencing both regulatory frameworks and pharmaceutical industry interactions.
Get started today with Solo access →
